Literature DB >> 9406671

Electrical remodelling of chronic atrial fibrillation.

C P Lau1, H F Tse.   

Abstract

1. It is now recognized that atrial fibrillation (AF) is not a benign condition, as it is associated with a 40% increase in mortality and a doubling of the risk of stroke. 2. The development of AF leads to mechanical, electrophysiological and cellular changes in the atria that tend to sustain AF. This process is known as atrial remodelling. 3. The three electrophysiological elements in the atria that initiate and sustain AF are: (i) shortening of the refractory period and an increase in dispersion; (ii) slowing of conduction velocity; and (iii) the presence of triggering foci. 4. As AF is a heterogeneous disorder, therapeutic strategies include the use of devices (pacemakers and atrial defibrillators), radiofrequency ablation (focal ablation or the creation of linear lines) and drug therapy that may reverse a remodelled atrium.

Entities:  

Mesh:

Year:  1997        PMID: 9406671     DOI: 10.1111/j.1440-1681.1997.tb02734.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  10 in total

Review 1.  [Current strategies in the treatment of atrial fibrillation].

Authors:  Imke Drewitz; Thomas Rostock; Boris Hoffmann; Daniel Steven; Helge Servatius; Thomas Meinertz; Stephan Willems
Journal:  Med Klin (Munich)       Date:  2008-11-15

2.  C-Reactive Protein and The Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  Venkata M Alla; Senthil Thambidorai; Kishlay Anand; Aryan N Mooss; Richard Baltaro; Syed M Mohiuddin
Journal:  J Atr Fibrillation       Date:  2010-01-01

3.  [Catheter ablation of persistent and long-standing persistent atrial fibrillation. Strategies and results].

Authors:  Daniel Steven; Arian Sultan; Benjamin Schäffer; Helge Servatius; Boris Hoffmann; Jakob Lüker; Stephan Willems
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-04-30

Review 4.  Inflammation and C-reactive protein in atrial fibrillation: cause or effect?

Authors:  Roberto Galea; Maria Teresa Cardillo; Annalisa Caroli; Maria Giulia Marini; Chiara Sonnino; Maria L Narducci; Luigi M Biasucci
Journal:  Tex Heart Inst J       Date:  2014-10-01

Review 5.  Strategies for pacemaker programming in acute heart failure.

Authors:  Marc K Lahiri; Justin T Mao; Claudio D Schuger
Journal:  Heart Fail Rev       Date:  2011-09       Impact factor: 4.214

6.  Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.

Authors:  C-J A Lindholm; O Fredholm; S-J Möller; N Edvardsson; T Kronvall; T Pettersson; V Firsovaite; A Roijer; C J Meurling; P G Platonov; S B Olsson
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

7.  Atrial fibrillation in patients with constrictive pericarditis: the significance of pericardial calcification.

Authors:  Gholam R Rezaian; Masoud Poor-Moghaddas; Javad Kojuri; Shahed Rezaian; Lida Liaghat; Najaf Zare
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

8.  High-resolution analysis of the surface P wave as a measure of atrial electrophysiological substrate.

Authors:  Damian P Redfearn; Joanne Lane; Kevin Ward; Peter J Stafford
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-01       Impact factor: 1.468

Review 9.  Postoperative Atrial Fibrillation Following Cardiac Surgery: From Pathogenesis to Potential Therapies.

Authors:  Yousef Rezaei; Mohammad Mehdi Peighambari; Shayan Naghshbandi; Niloufar Samiei; Alireza Alizadeh Ghavidel; Mohammad Reza Dehghani; Majid Haghjoo; Saeid Hosseini
Journal:  Am J Cardiovasc Drugs       Date:  2020-02       Impact factor: 3.571

10.  PITX2 upregulation increases the risk of chronic atrial fibrillation in a dose-dependent manner by modulating IKs and ICaL -insights from human atrial modelling.

Authors:  Jieyun Bai; Yaosheng Lu; Andy Lo; Jichao Zhao; Henggui Zhang
Journal:  Ann Transl Med       Date:  2020-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.